MiR-675 is over-expressed in patients with prostate cancer

Abnormal expression of miR-675 has been found in various human tumors. However, the expression pattern of miR-675 in prostate cancer patients and its clinical significance remain largely elusive. In the present study, we evaluated the expression status of miR-675 gene in 83 prostate cancer patients and 40 benign prostatic hyperplasia (BPH) cases using real-time quantitative PCR. The results revealed that miR-675 was significantly over-expressed in prostate cancer patients compared with BPH controls (P< 0.001). No significant difference between miR-675 over-expressed and low-expressed cases could be observed in age, differentiation grade, tumor size, lymph nodes stage, metastasis status, Gleason score or serum prostate-specific antigen (PSA) level. Receiver operating characteristic curve (ROC) analysis of miR-675 expression showed a great performance in distinguishing prostate cancer patients from controls with an area under the ROC curve (AUC) of 0.933 (P< 0.001). Our data suggest that the over-expression of miR-675 is a frequent event and might be a valuable diagnostic biomarker combination with PSA in prostate cancer patients.